3
Announcements
Trials
Browse
Landscape
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Observational
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Melanoma
8
Carcinoma, Non-Small-Cell Lung
8
Carcinoma, Hepatocellular
8
Squamous Cell Carcinoma of Head and Neck
6
Small Cell Lung Carcinoma
5
Neoplasms
4
Lung Neoplasms
4
Prostatic Neoplasms
3
Diabetes Mellitus, Insulin-Dependent, 12
3
Colorectal Neoplasms
3
Carcinoma, Renal Cell
3
Advanced Solid Tumors
3
Urinary Bladder Neoplasms
2
Recurrence
2
Lymphoma, Large B-Cell, Diffuse
2
Liver Neoplasms
2
Head and Neck Neoplasms
2
Biliary Tract Neoplasms
2
Urothelial Cancer
1
Unresectable Hepatocellular Carcinoma
1
Triple Negative Breast Neoplasms
1
Stomach Neoplasms
1
Solid Tumor
1
Platinum Refractory Extensive-Stage Small Cell Lung Carcinoma
1
Peritoneal Neoplasms
1
Part A and B: Advanced Solid Malignancies
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Non Small Cell Lung Cancer NSCLC
1
Non - Small Cell Lung Cancer NSCLC
1
Interventions
tremelimumab
1
durvalumab
1
atezolizumab
1
Bevacizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Unresectable Hepatocellular Carcinoma
×
tremelimumab
×
Clear all
NCT06117891
2026-05-12
REFINE-IO
Bayer
Active not recruiting
300 enrolled